Immunotherapy in Ovarian Cancer.
Natalia SiminiakRafał CzepczyńskiMikołaj Piotr ZaborowskiDariusz IżyckiPublished in: Archivum immunologiae et therapiae experimentalis (2022)
Despite advances in surgery and chemotherapy, ovarian cancer remains one of the most lethal malignancies. Hence, the implementation of novel treatment approaches is required to improve the outcomes of the disease. Immunotherapy has been proven to be effective in many tumors and has already been incorporated into clinical practice. In this review, we describe key strategies in immunotherapy of ovarian cancer and summarize data from clinical studies assessing immunological prospects which could improve ovarian cancer treatment approaches in the future. The most notable current strategies include checkpoint blockade agents, the use of vaccines, adoptive cell transfer, as well as various combinations of these methods. While several of these options are promising, large controlled randomized studies are still needed to implement new immunotherapeutic options into clinical practice.
Keyphrases
- clinical practice
- cell therapy
- current status
- minimally invasive
- dna damage
- primary care
- healthcare
- single cell
- open label
- cell cycle
- coronary artery bypass
- randomized controlled trial
- placebo controlled
- stem cells
- phase iii
- quality improvement
- squamous cell carcinoma
- metabolic syndrome
- oxidative stress
- mesenchymal stem cells
- phase ii